Promomed: Velgia (drug for the treatment of overweight and obesity)

Main article: Obesity

2024

Extension of Promomed Release Permit

Decree Governments of the Russian Federation No. 3930-r extended the use of inventions protected by patents the Danish Novo Nordisk until the end of 2025. GC Promomed will continue to produce a line of drugs based on semaglutide. The company announced this on December 28, 2024.

The number of patients suffering from obesity, metabolic disorders in our country alone totals more than 40 million people. This is almost half of the total working-age population in Russia. The problem has reached the scale of a pandemic. In this situation, the state and the pharmaceutical industry face the strategic task of providing each patient with the necessary drugs. PROMOMED has assumed this social responsibility,, and. in 2025, with the support of the state, it is ready to provide each patient with the necessary number of drugs, - said Ilya Bardin-Denisov, General Director of PROMOMED DM LLC.

PROMOMED was one of the first to receive permission to use patent-protected inventions. Such permission is issued on the basis of the conclusion of a special subcommittee on the use of inventions, utility models and industrial designs in order to ensure the economic security of Russia.

The entry into force of Order No. 3930-r will preserve on the domestic market the drugs "Quincenta" for the therapy of diabetes mellitus and "Velgiya" for the treatment of overweight and obesity. PROMOMED has developed its own solid-phase peptide synthesis technology for the release of these drugs, which, unlike the biotechnological method used in the release of original drugs, has a number of advantages. Russian development allows you to ensure the quality and highest safety profile of products, as well as remove the restrictions on scaling production that a foreign manufacturer faced.

PROMOMED's production facilities will fully provide patients in all regions of Russia with semaglutide-based drugs.

Start of "Velgia" registration

On October 4, 2024, Promomed PJSC announced the completion of the registration procedure for Velgia for the treatment of overweight and obesity of any severity.

The first batches of Velgia Group will be released into civil circulation in the 4th quarter of 2024. The sale of the drug through a commercial sales channel will ensure the wide availability of the drug for patients.

The drug Velgiya was created purposefully for the treatment of overweight and obesity - a non-infectious pandemic of our time, which has already covered more than half of the population of our country and the world. Velgia contains specially selected concentrations and increased dosages of the active substance, which increases its therapeutic effectiveness. The drug significantly reduces weight and contributes to the correction of metabolic disorders that underlie the formation of a number of cardiovascular and oncological diseases - the main causes of mortality in our country.

The launch of the drug for the treatment of overweight and obesity continues to implement its strategy presented as part of the initial placement of securities in July 2024 and aimed at strengthening its position in the most promising, volumetric and rapidly growing segments of the pharmaceutical market.